EPOMI Study: ErythroPOietin in Myocardial Infarction
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
EPOMI is a randomized, open-label, parallel phase II clinical study that will evaluate the
effects of a single erythropoietin administration on infarct size and cardiac remodeling in
patients with acute myocardial infarction. Eligible patients will be randomly assigned to
receive conventional therapy and single infusion of 1000U/kg of epoetin beta or conventional
therapy alone. Infarct size and cardiac remodeling parameters will be assessed by cardiac
magnetic resonance imaging (MRI) within 3-7 days of the randomization and repeated 3 months
later.
Phase:
Phase 2
Details
Lead Sponsor:
University Hospital, Angers
Collaborators:
Fédération Française de Cardiologie Société Française de Cardiologie